Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers
Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Filip Jankú(The University of Texas MD Anderson Cancer Center), David S. Hong(The University of Texas MD Anderson Cancer Center), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Vivek Subbiah(Sarah Cannon), Apostolia M. Tsimberidou(The University of Texas MD Anderson Cancer Center), Siqing Fu(The University of Texas MD Anderson Cancer Center), S. Greg Call(The University of Texas MD Anderson Cancer Center), Helen J. Huang(The University of Texas MD Anderson Cancer Center), Derek Dustin(Baylor College of Medicine), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Aung Naing(The University of Texas MD Anderson Cancer Center), Shubham Pant(The University of Texas MD Anderson Cancer Center), Daniel D. Karp(The University of Texas MD Anderson Cancer Center)
Cited by 52
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k